Pfizer's BRAFTOVI® Combination Therapy Demonstrates Significant Clinical Benefit in Metastatic Colorectal Cancer with BRAF V600E Mutation

 Pfizer Inc. (NYSE: PFE) announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination ...

January 27, 2025 | Monday | News
CG Pharmaceuticals Presents Promising Results for Ivaltinostat in Metastatic Pancreatic Cancer at ASCO GI Symposium

CG Pharmaceuticals (CG Pharma), a clinical biopharmaceutical company located in the San Francisco Bay Area, was established as an independent entity i...

January 24, 2025 | Friday | News
AstraZeneca Announces C$820 Million Investment in Ontario, Creating Over 700 High-Skilled Jobs

AstraZeneca, a global pharmaceutical company focused on developing life changing medicines,  announced a C$820 million (US$570m) investment in Canada,...

January 24, 2025 | Friday | News
Disc Medicine Announces Upsized $225.5 Million Public Offering of Common Stock and Pre-Funded Warrants

Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...

January 23, 2025 | Thursday | News
GC Cell Hosts First Thought Leadership Symposium in Jakarta, Showcasing Immuncell-LC’s Potential in Cancer Treatment

GC Cell, a leading cell and gene therapy company, announced the successful completion of its first thought leadership symposium in Jakarta, Indonesia....

January 23, 2025 | Thursday | News
Akeso’s Cadonilimab Combination Therapy Shows Landmark Survival Benefits in Advanced Gastric Cancer, Published in Nature Medicine

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine published the results of ...

January 23, 2025 | Thursday | News
EU Approves Sarclisa in Combination with VRd for Newly Diagnosed Multiple Myeloma Patients Ineligible for Stem Cell Transplant

Following the adoption of a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)...

January 23, 2025 | Thursday | News
Roche Receives FDA 510(k) Clearance and CLIA Waiver for Cobas® Liat STI Multiplex Assay Panels

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance and Clinical Laboratory Improvem...

January 23, 2025 | Thursday | News
ALX Oncology to Host Virtual Event on Updated Data from ASPEN-06 Trial of Evorpacept in HER2-Positive Advanced Gastric Cancer

ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing ther...

January 23, 2025 | Thursday | News
Xilio Therapeutics Presents Promising Phase 2 Data for Vilastobart in Combination with Atezolizumab in Metastatic MSS Colorectal Cancer

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies fo...

January 23, 2025 | Thursday | News
Stuart Therapeutics Completes Phase III Study of ST-100 for Dry Eye Disease, Topline Data Expected in February 2025

Stuart Therapeutics, Inc. (Stuart), a clinical-stage drug platform company developing novel therapies for ophthalmic diseases,  announced last patient...

January 23, 2025 | Thursday | News
Antennova Presents Promising Phase I/II Data for ATN-022 in Advanced Gastric Cancer at ASCO GI 2025

 Antennova, a clinical-stage biotech company focused on oncology announced the presentation of latest data from its Phase I/II CLINCH s...

January 23, 2025 | Thursday | News
Sanofi’s Opella Achieves FDA Approval to Initiate OTC Cialis Use Trial

Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on its planned a...

January 21, 2025 | Tuesday | News
Junshi Biosciences Partners with LEO Pharma to Launch Toripalimab in Europe

Shanghai Junshi Biosciences Co., Ltd , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercializati...

January 21, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close